Aura Biosciences, Inc. (AURA)

NASDAQ: AURA · IEX Real-Time Price · USD
9.24
+0.17 (1.87%)
At close: Mar 1, 2024, 4:00 PM
9.42
+0.18 (1.95%)
After-hours: Mar 1, 2024, 5:28 PM EST
1.87%
Market Cap 455.16M
Revenue (ttm) n/a
Net Income (ttm) -70.84M
Shares Out 49.20M
EPS (ttm) -1.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 86,969
Open 9.17
Previous Close 9.07
Day's Range 8.95 - 9.47
52-Week Range 5.99 - 13.50
Beta 0.29
Analysts Strong Buy
Price Target 21.00 (+127.27%)
Earnings Date Mar 13, 2024

About AURA

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial. The company was incorporated ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 29, 2021
Employees 70
Stock Exchange NASDAQ
Ticker Symbol AURA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for AURA stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 127.27% from the latest price.

Price Target
$21.0
(127.27% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Aura Biosciences to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indica...

6 days ago - Business Wire

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indica...

3 months ago - Business Wire

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indic...

4 months ago - Business Wire

Aura Biosciences Announces Pricing of Public Offering of Common Stock

BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncol...

4 months ago - Business Wire

Aura Biosciences Announces Proposed Public Offering of Common Stock

BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncol...

4 months ago - Business Wire

Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma

BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indic...

4 months ago - Business Wire

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indica...

4 months ago - Business Wire

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indica...

5 months ago - Business Wire

Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indica...

7 months ago - Business Wire

Aura Biosciences to Participate in the JMP Securities Life Sciences Conference

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indica...

10 months ago - Business Wire

Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indica...

10 months ago - Business Wire

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indic...

1 year ago - Business Wire

Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indica...

1 year ago - Business Wire

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indica...

1 year ago - Business Wire

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indica...

1 year ago - Business Wire

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indica...

1 year ago - Business Wire

Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022

BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indic...

1 year ago - Business Wire

Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncol...

1 year ago - Business Wire

Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncol...

1 year ago - Business Wire

Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indica...

1 year ago - Business Wire

Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple onco...

1 year ago - Business Wire

JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer"

JMP Securities has initiated the coverage on Aura Biosciences Inc (NASDAQ: AURA) with a Market Outperform rating and a $26 risk-adjusted price target. Aura is developing a targeted virus-like drug con...

1 year ago - Benzinga

Aura's stock jumps 11% after announcing Fast Track status for its bladder cancer treatment candidate

Shares of Aura Biosciences Inc. were up 11.3% in premarket trading on Thursday after the company said it received a Fast-Track designation from the Food and Drug Administration for its experimental bl...

1 year ago - Market Watch

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple onco...

1 year ago - Business Wire